-1.png)
Onkológia 5/2017
Primary treatment of metastatic prostate cancer
Over 50 years of treatment of primary metastatic prostate cancer was almost exclusively a matter of hormonal treatment. In 2015, docetaxel demonstrated a persistent prolongation of survival of more than a year. At present, the debate is about how to overcome this benefit. In our article we will deal with prognostic factors in the treatment of metastatic disease, primary hormone therapy, the possibilities of its combination with chemotherapy. We will approach the role of radiotherapy, surgical treatment as well as „new hormone therapy“ in the treatment of primary metastatic disease.
Keywords: prostate cancer, hormone sensitive disease, docetaxel
